ProCE Banner Activity

Islatravir Dose Optimization and Data on LA CAB + RPV in the Real World: Perspectives From Latin America

Clinical Thought

A modeling analysis of islatravir doses predicted that at 0.25 mg daily, lymphocyte changes would be similar to other ART regimens and effective concentrations would be reached. In the real-world US OPERA Cohort, long-acting cabotegravir plus rilpivirine was highly effective.

Released: November 22, 2022

Share

Faculty

Brenda E. Crabtree Ramírez

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Brenda E. Crabtree Ramírez, MD: consultant/advisor/speaker: GlaxoSmithKline, MSD.